1998
Prognostic indicators of survival in ALS
Stambler N, Charatan M, Cedarbaum J. Prognostic indicators of survival in ALS. Neurology 1998, 50: 66-72. PMID: 9443459, DOI: 10.1212/wnl.50.1.66.Peer-Reviewed Original ResearchConceptsStudy entrySerum chlorideMuscle strength lossBaseline demographic characteristicsLength of survivalRisk of mortalityClinical laboratory testsGreater weight lossCiliary neurotrophic factorRecombinant human ciliary neurotrophic factorHuman ciliary neurotrophic factorPlacebo groupPulmonary functionSymptom onsetPrognostic factorsMulticenter studyShorter survivalVital capacityNeurotrophic factorPrognostic indicatorRespiratory acidosisSurvival timeProbability of survivalDisease severityWeight loss
1991
Effect of MK-458 (HPMC) in Parkinson's Disease Previously Untreated With Dopaminergic Drugs. A Double-Blind, Placebo-Controlled Multicenter Study.
Koller WC, Block GA, Ahlskog JE, Ahrens S, Cedarbaum JM, Cyhan G, Goetz CG, LeWitt PA, Liss C, McLean L, Moses H, Muenter M, Nausieda P, Sanchez-Ramos J, Reich S, Singer C, Stellar S, Weiner W. Effect of MK-458 (HPMC) in Parkinson's Disease Previously Untreated With Dopaminergic Drugs. A Double-Blind, Placebo-Controlled Multicenter Study. Clinical Neuropharmacology 1991, 14: 322. PMID: 1913699, DOI: 10.1097/00002826-199108000-00004.Peer-Reviewed Original ResearchConceptsMK-458Early Parkinson's diseaseParkinson's diseaseDopaminergic drugsDisability Rating ScoreDopamine receptor agonismPlacebo-controlled evaluationPatient global assessmentClinical rating scalesParkinsonian symptomsAntiparkinsonian efficacyMulticenter studyAdverse reactionsIdeal treatmentReceptor agonistReceptor agonismSustained release formulationPlaceboGlobal assessmentDiseaseRating ScaleSignificant decreaseDrugsPatientsRating scores